Form 4 Filing for Arrowhead Pharmaceuticals, Inc.

On December 19, 2025, William Waddill, a director at Arrowhead Pharmaceuticals, Inc. (ARWR), reported the sale of 2,416 shares of Common Stock under a Rule 10b5-1 trading plan. The weighted average sale price was $66.66, with transactions ranging from $66.52 to $67.29. Following this transaction, Waddill directly owns 62,514 shares. Additionally, Waddill sold 5,451 shares at a weighted average price of $68.01 (ranging from $67.58 to $68.48), resulting in 57,063 shares owned. A further sale of 500 shares occurred at a weighted average price of $68.53 (ranging from $68.51 to $68.56), leaving 56,563 shares. These transactions were executed in accordance with a pre-arranged trading plan. The shares reported include those underlying Restricted Stock Units that may still be subject to vesting conditions.